Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression

TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling

(2016) Cai M. Roberts et al.   Scientific Reports

Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer

(2015) K-F Hsu et al.   BRITISH JOURNAL OF CANCER

miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin

(2015) X Zhu et al.   ONCOGENE

COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization

(2015) Yi-Hui Wu et al.   Oncotarget

Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma

(2015) Ying-Cheng Chiang et al.   Oncotarget

FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells

(2015) Wen-Tai Chiu et al.   Oncotarget

TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis

(2015) Sudhakar V. Nuti et al.   Oncotarget

The Role of TWIST in Ovarian Epithelial Cancers

(2014) Kyungbin Kim et al.   Korean Journal of Pathology

Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study

(2014) Katarzyna Marta Lisowska et al.   Frontiers in Oncology

Activation of NF-κB by SOD2 promotes the aggressiveness of lung adenocarcinoma by modulating NKX2-1-mediated IKKβ expression

(2013) Po-Ming Chen et al.   CARCINOGENESIS

COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer

(2013) Y-H Wu et al.   ONCOGENE

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Role of the Human High-Affinity Copper Transporter in Copper Homeostasis Regulation and Cisplatin Sensitivity in Cancer Chemotherapy

(2012) M. T. Kuo et al.   CANCER RESEARCH

Epithelial-Mesenchymal Transition Induced by TNF-  Requires NF- B-Mediated Transcriptional Upregulation of Twist1

(2012) C.-W. Li et al.   CANCER RESEARCH

Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition

(2012) H-O Jin et al.   Cell Death & Disease

Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile

(2011) Ardian Latifi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells

(2010) Masaki Shiota et al.   BJU INTERNATIONAL

Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator

(2010) Seiko Ishida et al.   CANCER CELL

Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

(2010) Panagiotis A. Konstantinopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed Cell Death Protein 4 Down-regulates Y-Box Binding Protein-1 Expression via a Direct Interaction with Twist1 to Suppress Cancer Cell Growth

(2009) M. Shiota et al.   CANCER RESEARCH

Sp1 Phosphorylation and Its Regulation of Gene Transcription

(2009) N. Y. Tan et al.   MOLECULAR AND CELLULAR BIOLOGY

Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway

(2008) Wen-Lei Zhuo et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS